- Trials with a EudraCT protocol (6,396)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
6,396 result(s) found for: Randomization.
Displaying page 1 of 320.
EudraCT Number: 2011-003474-86 | Sponsor Protocol Number: NCT0023595 | Start Date*: 2011-12-12 |
Sponsor Name:Myron D. Ginsberg | ||
Full Title: Albumin in Acute Stroke (ALIAS) Trial-Part 2: A Phase III Randomized Multicenter Clinical Trial of High-Dose Human Albumin Therapy for Neuroprotection in Acute Ischemic Stroke | ||
Medical condition: Acute Ischemic Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001770-29 | Sponsor Protocol Number: KKS-256 | Start Date*: 2019-11-19 |
Sponsor Name:Philipps-Universität Marburg | ||
Full Title: Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial (VIGILung) | ||
Medical condition: Prophylaxis against lung transplant rejection Clinical experience suggests that individual tailoring of immunosuppression for patients after lung transplantation could potentially optimize patient ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003936-25 | Sponsor Protocol Number: RLX0120 | Start Date*: 2020-10-31 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie... | |||||||||||||
Medical condition: Adult paucisymptomatic COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004188-28 | Sponsor Protocol Number: Monet | Start Date*: 2021-11-18 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Adaptative, Phase IV Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in N... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001759-17 | Sponsor Protocol Number: FGTW2101 | Start Date*: 2022-10-04 | |||||||||||
Sponsor Name:Laboratoire français du Fractionnement et des Biotechnologies (LFB BIOTECHNOLOGIES) | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients und... | |||||||||||||
Medical condition: Bleeding in patients undergoing complex cardiac surgery (involving CPB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002098-25 | Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID) | |||||||||||||
Medical condition: severe COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001608-40 | Sponsor Protocol Number: HS216C17(MRCT) | Start Date*: 2020-07-15 |
Sponsor Name:Zhejiang Hisun Pharmaceutical Co. Ltd. | ||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003431-33 | Sponsor Protocol Number: 19766 | Start Date*: 2020-03-05 | ||||||||||||||||
Sponsor Name:Bayer AG | ||||||||||||||||||
Full Title: Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic... | ||||||||||||||||||
Medical condition: Non-cardioembolic ischemic stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PT (Completed) FI (Completed) DE (Completed) NL (Completed) AT (Completed) FR (Completed) HU (Completed) DK (Completed) BE (Completed) BG (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002636-31 | Sponsor Protocol Number: APHP211034 | Start Date*: 2022-09-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI | ||
Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in... | ||
Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003975-80 | Sponsor Protocol Number: SHORTCUT | Start Date*: 2018-03-07 |
Sponsor Name:Academic Medical Center | ||
Full Title: Shorter treatment of catheter related urinary tract infections | ||
Medical condition: Catheter related urinary tract infection (CAUTI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003244-79 | Sponsor Protocol Number: 20603 | Start Date*: 2020-02-03 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial in... | |||||||||||||
Medical condition: Acute Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) HU (Completed) NL (Completed) DE (Completed) AT (Completed) ES (Completed) SE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003753-13 | Sponsor Protocol Number: P160909 | Start Date*: 2019-03-19 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | ||
Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | ||
Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002142-50 | Sponsor Protocol Number: POPCABG03 | Start Date*: 2019-04-09 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. | ||
Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001644-25 | Sponsor Protocol Number: ACE-ID-201/D822FC00001 | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:Acerta Pharma B.V. | |||||||||||||
Full Title: A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 | |||||||||||||
Medical condition: Subjects with life-threatening COVID-19 symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003941-41 | Sponsor Protocol Number: 0170 | Start Date*: 2019-08-09 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-000638-35 | Sponsor Protocol Number: CZOL446N2312 | Start Date*: 2004-09-15 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12... | ||
Medical condition: Postmenopausal Osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002612-31 | Sponsor Protocol Number: MANTICO | Start Date*: 2021-05-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004591-22 | Sponsor Protocol Number: HS-2017-01 | Start Date*: 2017-03-14 |
Sponsor Name:Medical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology | ||
Full Title: Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study | ||
Medical condition: Myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001768-39 | Sponsor Protocol Number: SURFABRON | Start Date*: 2018-03-07 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Randomized multicentre-controlled, placebo-controlled (1: 1) study to evaluate the efficacy and safety of Curosurf in patients under 12 months of age with moderate or severe acute respiratory distr... | |||||||||||||
Medical condition: Acute severe hypoxic bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001539-21 | Sponsor Protocol Number: CRAD001ADE36 | Start Date*: 2011-09-20 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen co... | |||||||||||||
Medical condition: lung transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
